Quiz Form

Question Date: 25/06/2023

Question: Which of the following is not true regarding aducanumab?

Options:

It is the first monoclonal antibody FDA approved in June 2021 for the treatment of mild to moderate Alzheimer's disease.
It is an anti Amyloid Beta immunotherapy that has demonstrated significant reduction in amyloid beta plaque burden as demonstrated by amyloid PET scan.
40 % patients on treatment with aducanumab had ARIA (Amyloid related imaging abnormalities) on MRI
The highest risk factor for ARIA is the presence of APOE4 allele

Correct Answer: It is the first monoclonal antibody FDA approved in June 2021 for the treatment of mild to moderate Alzheimer's disease.

Explaination: Aducanumab is the first monoclonal antibody FDA approved in June 2021 for the treatment of MCI due to AD and mild AD Dementia (MMSE> 23, Clinical Dementia Rating CDR of 0.5) It is an anti Amyloid Beta immunotherapy that has demonstrated significant reduction in amyloid beta plaque burden as demonstrated by amyloid PET scan The highest risk factor for ARIA is the presence of APOE4 allele.(40%, compared to 20% for non APOE4 allele patients) 40% patients on treatment with aducanumab had ARIA (Amyloid related imaging abnormalities) on MRI, and 7 % discontinued.

Reference: CONTINUUM (MINNEAP MINN) 2022;28(3, DEMENTIA):648-675 CONTINUUM (MINNEAP MINN) 2022;28(3,DEMENTIA):800-821 Alzheimers Dement. 2011 July ; 7(4): 367?385